IO-RESISTANT SQNSCLC

Clinical trials for IO-RESISTANT SQNSCLC explained in plain language.

Never miss a new study

Get alerted when new IO-RESISTANT SQNSCLC trials appear

Sign up with your email to follow new studies for IO-RESISTANT SQNSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug TAK-928 takes on tough lung cancer in major trial

Disease control Recruiting now

This phase 3 trial tests TAK-928, a drug designed to activate T cells inside tumors, against standard chemotherapy (docetaxel) in 600 adults with advanced non-small cell lung cancer that has worsened after prior treatments. The goal is to see if TAK-928 can shrink tumors or help …

Matched conditions: IO-RESISTANT SQNSCLC

Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control

Last updated Aug 06, 2026 00:00 UTC

IO-RESISTANT SQNSCLC

Get alerted when new IO-RESISTANT SQNSCLC trials appear

New drug TAK-928 takes on tough lung cancer in major trial